Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of July 2015, with a filing date of July 6, 2015. The registrant is a foreign private issuer based in Ness Ziona, Israel, reporting pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative performance data.
Material Changes
The primary material event disclosed is the announcement made on July 2, 2015, that BiondVax will cease trading on the NASDAQ stock exchange effective July 10, 2015. Concurrently, the company announced the launch of a new investor relations website.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the immediate operational change of delisting from NASDAQ. The document serves primarily to incorporate a press release by reference.
Investor Verification Checklist
- Verify the exact date and time of the final trading session on NASDAQ (July 10, 2015).
- Confirm the new trading venue or OTC status following the NASDAQ delisting.
- Review the attached press release (Exhibit 99.1) for the rationale behind the delisting and the new investor relations strategy.
- Check for any subsequent filings regarding the company's financial status post-delisting.